Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 554

1.

Why Are New Drugs Expensive and How Can They Stay Affordable?

Hammel B, Michel MC.

Handb Exp Pharmacol. 2019 Nov 7. doi: 10.1007/164_2019_301. [Epub ahead of print]

PMID:
31696349
2.

Building Robustness into Translational Research.

Erdogan BR, Michel MC.

Handb Exp Pharmacol. 2019 Oct 10. doi: 10.1007/164_2019_283. [Epub ahead of print]

PMID:
31598837
3.

Normalization of organ bath contraction data for tissue specimen size: does one approach fit all?

Erdogan BR, Karaomerlioglu I, Yesilyurt ZE, Ozturk N, Muderrisoglu AE, Michel MC, Arioglu-Inan E.

Naunyn Schmiedebergs Arch Pharmacol. 2019 Sep 11. doi: 10.1007/s00210-019-01727-x. [Epub ahead of print]

PMID:
31511953
4.

Urinary Bladder Weight and Function in a Rat Model of Mild Hyperglycemia and Its Treatment With Dapagliflozin.

Yesilyurt ZE, Erdogan BR, Karaomerlioglu I, Muderrisoglu AE, Michel MC, Arioglu-Inan E.

Front Pharmacol. 2019 Aug 16;10:911. doi: 10.3389/fphar.2019.00911. eCollection 2019.

5.

Sequential Multilingualism and Cognitive Abilities: Preliminary Data on the Contribution of Language Proficiency and Use in Different Modalities.

Boumeester M, Michel MC, Fyndanis V.

Behav Sci (Basel). 2019 Aug 26;9(9). pii: E92. doi: 10.3390/bs9090092.

6.

Is Dipstick Urinalysis Screening Beneficial in Men with Lower Urinary Tract Symptoms?

Lowe FC, Michel MC, Wruck JM, Verbeek AE.

Adv Ther. 2019 Oct;36(10):2954-2967. doi: 10.1007/s12325-019-01042-0. Epub 2019 Aug 7.

7.

Cognitive and mood side effects of lower urinary tract medication.

Muderrisoglu AE, Becher KF, Madersbacher S, Michel MC.

Expert Opin Drug Saf. 2019 Oct;18(10):915-923. doi: 10.1080/14740338.2019.1652269. Epub 2019 Aug 8. Review.

PMID:
31373245
8.

Desensitization of cAMP Accumulation via Human β3-Adrenoceptors Expressed in Human Embryonic Kidney Cells by Full, Partial, and Biased Agonists.

Okeke K, Michel-Reher MB, Gravas S, Michel MC.

Front Pharmacol. 2019 Jun 7;10:596. doi: 10.3389/fphar.2019.00596. eCollection 2019.

9.

Adrenoceptors-New roles for old players.

Michel MC, Bond RA, Summers RJ.

Br J Pharmacol. 2019 Jul;176(14):2339-2342. doi: 10.1111/bph.14701.

PMID:
31240712
10.

β3 -Adrenoceptors in the normal and diseased urinary bladder-What are the open questions?

Igawa Y, Aizawa N, Michel MC.

Br J Pharmacol. 2019 Jul;176(14):2525-2538. doi: 10.1111/bph.14658. Epub 2019 May 3. Review.

PMID:
30868554
11.

A cost effective custom dental guard for transoral robotic surgery.

Benito D, Michel MC, Thakkar PG, Goodman JF, Sadeghi N, Joshi AS.

J Robot Surg. 2019 Mar 2. doi: 10.1007/s11701-019-00942-1. [Epub ahead of print]

PMID:
30826917
12.

Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?

Okeke K, Angers S, Bouvier M, Michel MC.

Br J Pharmacol. 2019 Jul;176(14):2539-2558. doi: 10.1111/bph.14633. Epub 2019 Apr 7. Review.

PMID:
30809805
13.

Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Arioglu-Inan E, Kayki-Mutlu G, Michel MC.

Br J Pharmacol. 2019 Jul;176(14):2482-2495. doi: 10.1111/bph.14635. Epub 2019 Apr 22. Review.

PMID:
30801686
14.

[Do benign prostatic hyperplasia drugs affect mood or cognition?]

Becher KF, Madersbacher S, Michel MC.

Urologe A. 2019 Mar;58(3):248-253. doi: 10.1007/s00120-019-0871-z. Review. German.

PMID:
30762077
15.

Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.

Shalgunov V, van Waarde A, Booij J, Michel MC, Dierckx RAJO, Elsinga PH.

Med Res Rev. 2019 May;39(3):1014-1052. doi: 10.1002/med.21552. Epub 2018 Nov 18. Review.

16.

Treatment of Bladder Pain Syndrome: One Size May Not Fit All.

Peyronnet B, Pape DM, Michel MC, Brucker BM.

Eur Urol. 2018 Nov;74(5):631-632. doi: 10.1016/j.eururo.2018.08.015. Epub 2018 Aug 31. No abstract available.

PMID:
30177285
17.

A systematic review of urinary bladder hypertrophy in experimental diabetes: Part 2. Comparison of animal models and functional consequences.

Ellenbroek JH, Arioglu Inan E, Michel MC.

Neurourol Urodyn. 2018 Nov;37(8):2346-2360. doi: 10.1002/nau.23786. Epub 2018 Aug 28.

PMID:
30152546
18.

Commentary on the BJP's new statistical reporting guidelines.

Motulsky HJ, Michel MC.

Br J Pharmacol. 2018 Sep;175(18):3636-3637. doi: 10.1111/bph.14441. No abstract available.

19.

Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic Hyperplasia.

Madersbacher S, Michel MC.

Eur Urol. 2018 Oct;74(4):522-523. doi: 10.1016/j.eururo.2018.07.013. Epub 2018 Jul 26. No abstract available.

PMID:
30057132
20.

Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations.

Kardos P, Beeh KM, Sent U, Mueck T, Gräter H, Michel MC.

BMC Pharmacol Toxicol. 2018 Jul 4;19(1):40. doi: 10.1186/s40360-018-0229-y.

21.

Do review articles boost journal impact factors? A longitudinal analysis for five pharmacology journals.

Amiri M, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Sep;391(9):1033-1035. doi: 10.1007/s00210-018-1529-x. Epub 2018 Jun 21.

PMID:
29926117
22.

Modulation of lower urinary tract smooth muscle contraction and relaxation by the urothelium.

Sellers D, Chess-Williams R, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Jul;391(7):675-694. doi: 10.1007/s00210-018-1510-8. Epub 2018 May 28. Review.

PMID:
29808232
23.

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

Peyronnet B, Brucker BM, Michel MC.

Eur Urol Focus. 2018 Jan;4(1):17-24. doi: 10.1016/j.euf.2018.04.005. Epub 2018 Apr 14. Review.

PMID:
29665997
24.

Causes and circumstances of death in a neonatal unit over 20 years.

Michel MC, Colaizy TT, Klein JM, Segar JL, Bell EF.

Pediatr Res. 2018 Apr;83(4):829-833. doi: 10.1038/pr.2018.1. Epub 2018 Feb 14.

25.

A systematic review of urinary bladder hypertrophy in experimental diabetes: Part I. Streptozotocin-induced rat models.

Arioglu Inan E, Ellenbroek JH, Michel MC.

Neurourol Urodyn. 2018 Apr;37(4):1212-1219. doi: 10.1002/nau.23490. Epub 2018 Feb 2.

PMID:
29392751
26.

Biased Agonism in Drug Discovery-Is It Too Soon to Choose a Path?

Michel MC, Charlton SJ.

Mol Pharmacol. 2018 Apr;93(4):259-265. doi: 10.1124/mol.117.110890. Epub 2018 Jan 11. Review.

PMID:
29326242
27.

Muscarinic type-1 receptors contribute to IK,ACh in human atrial cardiomyocytes and are upregulated in patients with chronic atrial fibrillation.

Heijman J, Kirchner D, Kunze F, Chrétien EM, Michel-Reher MB, Voigt N, Knaut M, Michel MC, Ravens U, Dobrev D.

Int J Cardiol. 2018 Mar 15;255:61-68. doi: 10.1016/j.ijcard.2017.12.050. Epub 2017 Dec 22.

28.

Innovation in cardiovascular disease in Europe with focus on arrhythmias: current status, opportunities, roadblocks, and the role of multiple stakeholders.

Prinzen FW, Dagres N, Bollmann A, Arnar DO, Bove S, Camm J, Casadei B, Kirchhof P, Kuck KH, Lumens J, Michel MC, Schwartz PJ, Van Vleymen B, Vardas P, Hindricks G.

Europace. 2018 May 1;20(5):733-738. doi: 10.1093/europace/eux095.

PMID:
28605436
29.

Revised editorial guidelines for manuscripts on the pharmacology of plant extracts.

Merfort I, Michel MC, Seifert R.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Aug;390(8):765-766. doi: 10.1007/s00210-017-1390-3. Epub 2017 Jun 6. No abstract available.

PMID:
28585064
30.

The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism?

Mo W, Michel MC, Lee XW, Kaumann AJ, Molenaar P.

Br J Pharmacol. 2017 Aug;174(16):2706-2715. doi: 10.1111/bph.13897. Epub 2017 Jul 7.

31.

Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?

Okeke K, Gravas S, Michel MC.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F859-F861. doi: 10.1152/ajprenal.00215.2017. Epub 2017 May 17. No abstract available.

32.

Denominator changes may obscure results from single-well assays: β3-adrenoceptor ligand-induced changes of cell number as example.

Okeke K, Michel-Reher MB, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Jul;390(7):761-763. doi: 10.1007/s00210-017-1380-5. Epub 2017 May 4. No abstract available.

PMID:
28474169
33.

[How can innovative medicines stay affordable?]

Michel MC.

MMW Fortschr Med. 2017 Apr;159(6):65-67. doi: 10.1007/s15006-017-9487-7. Review. German. No abstract available.

PMID:
28374360
34.

Editorial on "Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study".

Michel MC.

Neurourol Urodyn. 2017 Nov;36(8):2192. doi: 10.1002/nau.23238. Epub 2017 Feb 21. No abstract available.

PMID:
28220531
35.

Re: The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.

Michel MC.

Eur Urol. 2017 May;71(5):834-835. doi: 10.1016/j.eururo.2017.01.029. Epub 2017 Jan 26. No abstract available.

PMID:
28131465
36.

Opportunities and Challenges for Drug Development: Public-Private Partnerships, Adaptive Designs and Big Data.

Yildirim O, Gottwald M, Schüler P, Michel MC.

Front Pharmacol. 2016 Dec 6;7:461. doi: 10.3389/fphar.2016.00461. eCollection 2016. Review.

37.

Factors associated with efficacy of an ibuprofen/pseudoephedrine combination drug in pharmacy customers with common cold symptoms.

Klimek L, Schumacher H, Schütt T, Gräter H, Mueck T, Michel MC.

Int J Clin Pract. 2017 Feb;71(2). doi: 10.1111/ijcp.12907. Epub 2016 Dec 7.

38.

Editorial Comment.

Michel MC.

J Urol. 2016 Dec;196(6):1808. doi: 10.1016/j.juro.2016.05.142. Epub 2016 Aug 24. No abstract available.

PMID:
27565771
39.

Impact of Formulation on the Pharmacokinetic Profile of Dutasteride.

Michel MC.

Clin Drug Investig. 2016 Sep;36(9):769-770. doi: 10.1007/s40261-016-0429-4. No abstract available.

PMID:
27364517
40.

β-Adrenoceptor-mediated Relaxation of Urinary Bladder Muscle in β2-Adrenoceptor Knockout Mice.

Propping S, Lorenz K, Michel MC, Wirth MP, Ravens U.

Front Pharmacol. 2016 May 9;7:118. doi: 10.3389/fphar.2016.00118. eCollection 2016.

41.

Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat.

Steubl D, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Aug;389(8):815-7. doi: 10.1007/s00210-016-1260-4. Epub 2016 May 25. No abstract available.

PMID:
27220331
42.

Angiotensin II type 1 receptor antagonists in animal models of vascular, cardiac, metabolic and renal disease.

Michel MC, Brunner HR, Foster C, Huo Y.

Pharmacol Ther. 2016 Aug;164:1-81. doi: 10.1016/j.pharmthera.2016.03.019. Epub 2016 Apr 27. Review.

44.

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.

Michel MC, Gravas S.

Expert Opin Drug Saf. 2016 May;15(5):647-57. doi: 10.1517/14740338.2016.1160055. Epub 2016 Mar 21. Review.

PMID:
26954275
45.

Pathophysiological Factors in the Relationship between Chronological Age and Calculated Lung Age as Detected in a Screening Setting in Community-Dwelling Subjects.

Kardos P, Schütt T, Mück T, Schumacher H, Michel MC.

Front Med (Lausanne). 2016 Feb 3;3:2. doi: 10.3389/fmed.2016.00002. eCollection 2016.

46.

How β3 -adrenoceptor-selective is mirabegron?

Michel MC.

Br J Pharmacol. 2016 Feb;173(3):429-30. doi: 10.1111/bph.13379. No abstract available.

47.

β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project.

Michel MC, Korstanje C.

Pharmacol Ther. 2016 Mar;159:66-82. doi: 10.1016/j.pharmthera.2016.01.007. Epub 2016 Jan 22. Review.

PMID:
26808167
48.

Preclinical research strategies for newly approved drugs as reflected in early publication patterns.

Köster U, Nolte I, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Feb;389(2):187-99. doi: 10.1007/s00210-015-1187-1. Epub 2015 Nov 26.

PMID:
26612507
49.

Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs.

Köster U, Nolte I, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2016 Feb;389(2):201-9. doi: 10.1007/s00210-015-1185-3. Epub 2015 Nov 26.

PMID:
26612506
50.

Regulation of GAPDH expression by treatment with the β-adrenoceptor agonist isoprenaline--is GADPH a suitable loading control in immunoblot experiments?

Michel-Reher MB, Michel MC.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Oct;388(10):1119-20. doi: 10.1007/s00210-015-1166-6. Epub 2015 Aug 18. No abstract available.

PMID:
26278281

Supplemental Content

Loading ...
Support Center